Subscribe
Subscribe

ElmediX raises nearly 12 million euros to develop innovative heat technology to fight cancer

Mechelen, Belgium, January 25, 2022 - Belgian company ElmediX is developing intensive and controlled heat treatments for the treatment of cancer. A new capital injection of 4M euros brings the total to almost 12M euros (including VLAIO research grants worth 1.8M euros) and accelerates the trajectory of this innovative MedTech company.

V-Bio Ventures participates in the EUR 12 million seed round of heart failure biotech Corteria Pharmaceuticals

Ghent, Belgium, 9 December 2021 – Corteria Pharmaceuticals, a French biotechnology company specialized in the development of interceptive therapies for heart failure subpopulations, today announced the successful completion of its Seed round, providing EUR 12 million to pursue the development of a series of programs in-licensed from Sanofi S.A. (Paris, France). The seed round was led by Kurma Partners and includes V-Bio Ventures, Omnes Capital, and InVivo Capital. As part of the financing, Thierry Laugel (Chair) and Peter Neubeck from Kurma Partners, Ward Capoen from V-Bio Ventures, Claire Poulard from Omnes Capital, and Luis Pareras from InVivo Capital Health will join the Board of Directors.

New start-up Trince raises EUR 4 million for innovative technology to produce personalized cancer therapies safer, cheaper, and faster

Rejuvenate Biomed: Expanding peoples’ health spans by boosting cell resilience

Aging will affect each and every one of us at some point; it is part of the covenant of life. However, just as we have learned to treat and prevent various forms of cancers and cardiovascular diseases, there are numerous ways which we can improve peoples’ health spans. Rejuvenate Biomed is a young Belgian company in this field, leveraging safe prescription drugs to improve cell resilience and help us stay well for longer.

Belgium has all the ingredients to be a top country for data science in health – but we have to act now!

Rejuvenate Biomed raises a EUR 15.7 million Series B to accelerate clinical development of its sarcopenia treatment for healthy aging

Heusden-Zolder, Belgium, Schlieren, Zürich, Switzerland, and Luxembourg, Grand Duchy of Luxembourg, 12 October 2021 – Rejuvenate Biomed NV (‘Rejuvenate’), a biomedical company developing novel combination drugs for age-related diseases, today announces a EUR 15.7 million Series B round. The funding is being used to accelerate the clinical development of Rejuvenate’s lead candidate RJx-01 in both acute and chronic sarcopenia (disuse-induced and age-related muscle failure).

EsoBiotec ready to transform cell therapy cancer treatments

A vision of the future: smart contact lenses to treat patients with iris disorders and light sensitivity

A woman opens her front door and looks to the sky to judge the weather. It’s sunny and inside her contact lenses, tiny microchips switch on layers of liquid crystals to protect her eyes from the bright light. Satisfied she won’t need a raincoat, the woman steps onto the street and goes about her day. It might sound like the start of a sci-fi novel, but this is the reality of Azalea Vision’s smart tech.

Newton Biocapital invests in PRISM BioLab to support development of a unique peptide mimetic technology platform to discover new drugs for intractable diseases

Spectricity Raises €14 Million Series B Funding as it Accelerates Plans to Deliver Industry Leading Hyperspectral Sensing to Mobile and Consumer Devices

Funding Expands Growth for Tiny Chip-size Sensors for Unimaginable New Applications.

Ardena’s success leads to major €35 million investment for expansion in Belgium, Sweden and The Netherlands

Azalea Vision closes € 8 million Series A to develop a smart contact lens for light sensitivity and ocular disorders

Azalea Vision develops autonomous smart solutions embedded inside a contact lens to improve the quality of life of people with light sensitivity or ocular disorders. The company has announced the closing of its Series A funding round, comprised of € 6.2 million in equity and € 1.8 million as a non-dilutive grant.

Newton Biocapital invests in EditForce to support development of a unique DNA/RNA editing platform based on PPR protein technology

Newton Biocapital invests in NeuVasQ: EUR 20 million Series A to develop unique blood-brain barrier therapy

Montis Biosciences Awarded VLAIO Grant to Expand its Pipeline of Novel Immune-Oncology Therapeutics